Zymeworks Expects $324M Cash Resources, Plus $25M Milestone, To Fund Operations Into 2H-2027
Zymeworks Expects $324M Cash Resources, Plus $25M Milestone, To Fund Operations Into 2H-2027
Updated Cash Runway Guidance
更新的現金維持指導
As of December 31, 2024, the Company had cash resources of approximately $324 million (unaudited), consisting of cash, cash equivalents, and marketable securities, not including a $25 million milestone payment earned in 4Q-2024 from Jazz Pharmaceuticals which is expected to be received in 1Q-2025. Based on current operating plans and assuming receipt of certain anticipated regulatory milestones, we continue to expect our existing cash resources, when combined with such anticipated milestone payments, will enable us to fund planned operations into 2H-2027.
截至2024年12月31日，公司擁有現金資源約爲$32400萬（未經審計），包括現金、現金等價物和可交易證券，不包括預計將在2025年第一季度收到的來自爵士製藥的$2500萬里程碑付款，該筆付款是在2024年第四季度獲得的。基於當前的運營計劃，並假設收到某些預期的監管里程碑，我們繼續預計，現有的現金資源與這些預期的里程碑付款結合起來，將使我們能夠資助計劃的運營直到2027年下半年。
譯文內容由第三人軟體翻譯。
